dbl™ irinotecan injection concentrate
pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection - dbl™ irinotecan injection concentrate is indicated as a component of first line treatment of patients with metastatic carcinoma of the colon or rectum. irinotecan injection concentrate is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
meditab irinotecan irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial
cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
meditab irinotecan irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial
cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
camptosar
pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml; ; - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection
irinotecan-dp irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial
medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan-ga irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial
medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan-dp irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial
medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan-ga irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial
medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan
viatris limited - irinotecan hydrochloride trihydrate 20 mg/ml equivalent to 17.33 mg irinotecan; ; - concentrate for infusion - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml equivalent to 17.33 mg irinotecan excipient: lactic acid sodium hydroxide sorbitol water for injection - irinotecan concentrate for infusion is indicated for the first line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with 5fu/leucovorin. irinotecan concentrate for infusion is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan accord 20 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors